Suven Life Sciences Limited (SUVEN.BO)
INR 121.7
(2.4%)
INR 121.7
(2.4%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.84 Billion INR | -26.74% |
| 2022 | 3.88 Billion INR | 259.99% |
| 2021 | 1.08 Billion INR | -15.87% |
| 2020 | 1.28 Billion INR | -29.41% |
| 2019 | 1.81 Billion INR | -40.03% |
| 2018 | 3.03 Billion INR | -67.0% |
| 2017 | 9.19 Billion INR | 12.68% |
| 2016 | 8.15 Billion INR | 8.55% |
| 2015 | 7.51 Billion INR | 0.79% |
| 2014 | 7.45 Billion INR | 53.22% |
| 2013 | 4.86 Billion INR | 48.54% |
| 2012 | 3.27 Billion INR | 14.96% |
| 2011 | 2.84 Billion INR | 27.43% |
| 2010 | 2.23 Billion INR | 9.22% |
| 2009 | 2.04 Billion INR | 10.0% |
| 2008 | 1.86 Billion INR | -6.24% |
| 2007 | 1.98 Billion INR | 14.6% |
| 2006 | 1.73 Billion INR | 21.13% |
| 2005 | 1.43 Billion INR | 5.34% |
| 2004 | 1.35 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.11 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 2.84 Billion INR | -26.74% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 2.84 Billion INR | 0.0% |
| 2023 Q2 | 3.5 Billion INR | 0.0% |
| 2022 Q2 | 1.2 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 3.88 Billion INR | 259.99% |
| 2022 Q4 | 3.88 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 626.69 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 1.08 Billion INR | -15.87% |
| 2021 Q4 | 1.08 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 1.28 Billion INR | -29.41% |
| 2020 Q2 | 1.42 Billion INR | 0.0% |
| 2020 Q4 | 1.28 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 1.81 Billion INR | -40.03% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 12.37 Billion INR | 0.0% |
| 2019 Q4 | 1.81 Billion INR | 0.0% |
| 2018 FY | 3.03 Billion INR | -67.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 Q4 | 3.03 Billion INR | 0.0% |
| 2017 FY | 9.19 Billion INR | 12.68% |
| 2016 FY | 8.15 Billion INR | 8.55% |
| 2016 Q4 | 8.15 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 7.51 Billion INR | 0.79% |
| 2015 Q4 | 7.51 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 8.12 Billion INR | 0.0% |
| 2014 Q4 | 7.45 Billion INR | 0.0% |
| 2014 Q2 | 5.05 Billion INR | 0.0% |
| 2014 FY | 7.45 Billion INR | 53.22% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 FY | 4.86 Billion INR | 48.54% |
| 2013 Q4 | 4.86 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 4.48 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q2 | 6.36 Billion INR | 0.0% |
| 2012 Q4 | 3.27 Billion INR | 0.0% |
| 2012 FY | 3.27 Billion INR | 14.96% |
| 2011 FY | 2.84 Billion INR | 27.43% |
| 2010 FY | 2.23 Billion INR | 9.22% |
| 2009 FY | 2.04 Billion INR | 10.0% |
| 2008 FY | 1.86 Billion INR | -6.24% |
| 2007 FY | 1.98 Billion INR | 14.6% |
| 2006 FY | 1.73 Billion INR | 21.13% |
| 2005 FY | 1.43 Billion INR | 5.34% |
| 2004 FY | 1.35 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 95.58% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 99.368% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 90.005% |
| Granules India Limited | 55.2 Billion INR | 94.84% |
| Indoco Remedies Limited | 21.44 Billion INR | 86.716% |
| Achyut Healthcare Limited | 309.52 Million INR | -820.46% |
| Ajanta Pharma Limited | 46.38 Billion INR | 93.858% |
| Alkem Laboratories Limited | 155.74 Billion INR | 98.171% |
| Alpa Laboratories Limited | 1.82 Billion INR | -56.007% |
| Brooks Laboratories Limited | 904.45 Million INR | -215.0% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | 73.572% |
| Bajaj HealthCare Limited | 7.65 Billion INR | 62.764% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 76.529% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 99.265% |
| Eris Lifesciences Limited | 70.48 Billion INR | 95.958% |
| FDC Limited | 24.68 Billion INR | 88.457% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 98.016% |
| Gufic Biosciences Limited | 10.92 Billion INR | 73.923% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 75.547% |
| Ipca Laboratories Limited | 111.01 Billion INR | 97.434% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -31.244% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -59.901% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -88.841% |
| Laurus Labs Limited | 83.87 Billion INR | 96.603% |
| Lupin Limited | 239.97 Billion INR | 98.813% |
| Mankind Pharma Limited | 119.63 Billion INR | 97.619% |
| Medicamen Biotech Limited | 2.94 Billion INR | 3.266% |
| Medico Remedies Limited | 961.95 Million INR | -196.171% |
| Megasoft Limited | 3.65 Billion INR | 22.136% |
| NATCO Pharma Limited | 69.06 Billion INR | 95.875% |
| Piramal Pharma Limited | 153.11 Billion INR | 98.139% |
| RPG Life Sciences Limited | 5.12 Billion INR | 44.449% |
| Sigachi Industries Limited | 6.94 Billion INR | 58.957% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 99.667% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 87.361% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | 29.595% |
| Unichem Laboratories Limited | 31.69 Billion INR | 91.011% |
| Wanbury Limited | 3.43 Billion INR | 17.057% |
| Windlas Biotech Limited | 6.26 Billion INR | 54.503% |
| ZIM Laboratories Limited | 4.46 Billion INR | 36.238% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 99.027% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | 44.683% |
| Divi's Laboratories Limited | 154.7 Billion INR | 98.158% |
| Hester Biosciences Limited | 6.62 Billion INR | 56.986% |
| Procter & Gamble Health Limited | 7.94 Billion INR | 64.134% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | 22.342% |
| Bal Pharma Limited | 3.2 Billion INR | 11.076% |
| Strides Pharma Science Limited | 58.39 Billion INR | 95.121% |
| Venus Remedies Limited | 6.26 Billion INR | 54.549% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 88.966% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 86.997% |
| Shilpa Medicare Limited | 30.93 Billion INR | 90.789% |
| Aarti Drugs Limited | 24.32 Billion INR | 88.287% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 87.306% |
| Ind-Swift Limited | 6.54 Billion INR | 56.468% |
| Valiant Laboratories Limited | 3.42 Billion INR | 16.862% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 92.867% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | 87.881% |
| Themis Medicare Limited | 5.66 Billion INR | 49.701% |
| Hikal Limited | 24.87 Billion INR | 88.545% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 98.108% |
| Sequent Scientific Limited | 15.4 Billion INR | 81.504% |
| Novartis India Limited | 9.24 Billion INR | 69.197% |
| Wockhardt Limited | 76.49 Billion INR | 96.275% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 97.533% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -505.111% |
| Neuland Laboratories Limited | 18.32 Billion INR | 84.453% |
| Morepen Laboratories Limited | 12.93 Billion INR | 77.969% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -18.679% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | 14.552% |